Oncology

ESMO 2024

ESMO 2024 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ESMO 2024

1 October 2024 09:48

Meet the Trialist: Prof. Fred Saad shares insights from the ARANOTE trial

Expert

Prof. Fred Saad, University of Montreal Hospital Center Research Center, Canada

Trial

Phase 3, ARANOTE

Conference

ESMO 2024

25 September 2024 16:42

ESMO 2024 Focus on GU Oncology Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ESMO 2024

19 September 2024 21:56

Adjuvant durvalumab does not improve survival in completely resected NSCLC

Presented By

Prof. Glenwood Goss, Ottawa Hospital, Canada

Trial

Phase 3, BR.31

Conference

ESMO 2024

Type

News article

19 September 2024 11:47

Both NICHE-2 and NICHE-3 trials show high efficiency of short neoadjuvant immunotherapy in dMMR colon cancer

Presented By

Dr Myriam Chalabi, Netherlands Cancer Institute, the Netherlands; Dr Peter de Gooyer, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NICHE

Conference

ESMO 2024

Type

News article

19 September 2024 11:43

Adding lenvatinib plus pembrolizumab to TACE improves survival in intermediate-stage hepatocellular cancer

Presented By

Prof. Josep Llovet, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, LEAP-012

Conference

ESMO 2024

Type

News article

19 September 2024 11:41

High pCR rates with dual neoadjuvant immunotherapy in TIL-high TNBC

Presented By

Dr Iris Nederlof, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, BELLINI

Conference

ESMO 2024

Type

News article

19 September 2024 11:39

Doublet maintenance therapy does not outperform monotherapy in ovarian cancer

Presented By

Dr Bradley Monk, University of Arizona, AZ, USA

Trial

Phase 3, ATHENA-COMBO

Conference

ESMO 2024

Type

News article

19 September 2024 11:37

Faecal transplants show promise in enhancing metastatic RCC treatment

Presented By

Dr Chiara Ciccarese, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Trial

Phase 2, TACITO

Conference

ESMO 2024

Type

News article

18 September 2024 13:55

177Lu-PSMA effective both in mCRPC and mHSPC

Presented By

Dr Oliver Sartor, Tulane University, LA, USA; Dr Arun Azad, Peter MacCallum Cancer Center, Australia

Trial

SPLASH, UpFrontPSMA

Conference

ESMO 2024

Type

News article

18 September 2024 11:59

Combination of radium-223 and enzalutamide benefits mCRPC patients with bone metastases

Presented By

Prof. Silke Gillessen, Oncology Institute of Southern Switzerland

Trial

Phase 3, PEACE-3

Conference

ESMO 2024

Type

News article

18 September 2024 11:57

Breastfeeding does not increase the risk of breast cancer recurrence

Presented By

Dr Fedro Peccatori, European Institute of Oncology, Italy; Dr Eva Blondeaux, University of Genova, Italy

Trial

POSITIVE, BRCA BCY Collaboration

Conference

ESMO 2024

Type

News article

18 September 2024 11:55

Increased OS with pembrolizumab in newly diagnosed, high-risk, locally advanced cervical cancer

Presented By

Prof. Domenica Lorusso, Humanitas San Pio X, Italy

Trial

Phase 3, KEYNOTE-A18

Conference

ESMO 2024

Type

News article

18 September 2024 11:52

Perioperative durvalumab combined with neoadjuvant chemotherapy improves survival in bladder cancer

Presented By

Dr Thomas Powles, Barts Cancer Center, UK

Trial

Phase 3, NIAGARA

Conference

ESMO 2024

Type

News article

18 September 2024 11:49

Darolutamide plus ADT shows significant benefit in mHSPC: ARANOTE

Presented By

Prof. Fred Saad, Centre Hospitalier de l’Université de Montréal, Canada

Trial

Phase 3, ARANOTE

Conference

ESMO 2024

Type

News article

18 September 2024 10:53

Rethinking immune rechallenge: Tivozanib monotherapy emerges as a promising post-ICI option in metastatic RCC

Presented By

Prof. Toni Choueiri, Dana Farber Cancer Institute at Harvard University, Boston, MA, USA

Trial

Phase 3, TiNivo-2

Conference

ESMO 2024

Type

News article

17 September 2024 12:49

Retifanlimab boosts survival in patients with anal cancer

Presented By

Dr Sheela Rao, Royal Marsden, UK

Trial

Phase 3, POD1UM-303/InterAACT 2

Conference

ESMO 2024

Type

News article

17 September 2024 11:31

Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma

Presented By

Dr Minke Lucas, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, NADINA

Conference

ESMO 2024

Type

News article

17 September 2024 11:27

Neoadjuvant chemoradiation does not improve surgical outcome nor survival in pancreatic cancer

Presented By

Dr Aurélien Lambert, Lorraine Cancer Institute, France

Trial

Phase 2, PANDAS/PRODIGE 44

Conference

ESMO 2024

Type

News article

17 September 2024 11:26

Trastuzumab deruxtecan also effective in patients with brain metastases

Presented By

Dr Nancy Lin, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, DESTINY-Breast12

Conference

ESMO 2024

Type

News article

17 September 2024 11:24

NVL-655: a promising new option in pretreated, drug-resistant ALK-mutated NSCLC

Presented By

Dr Alexander Drilon, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 1/2, ALKOVE-1

Conference

ESMO 2024

Type

News article

17 September 2024 11:21

Final OS for CONTACT-02 trial in metastatic castration-resistant prostate cancer

Presented By

Prof. Neeraj Agarwal, Huntsman Cancer Institute, UT, USA

Trial

Phase 3, CONTACT-02

Conference

ESMO 2024

Type

News article

17 September 2024 10:43

ESMO GI 2024

OS benefit in ARMANI, but is it worth it?

Presented By

Dr Giovanni Randon, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 3, ARMANI

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:08

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Conference

ESMO GI 2024

21 August 2024 12:05

SPOTLIGHT on new targets in immunotherapy: claudin 18.2

Presented By

Prof. Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, SPOTLIGHT

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:03

AI facilitates early detection of hepatocellular carcinoma

Presented By

Dr Kin Nam Kwok, Hong Kong University, Hong Kong

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:59

Encouraging efficacy of anti-claudin 18.2 ADC in G/GEJ cancer

Presented By

Dr Jia Liu, St Vincent’s Hospital Sydney, Australia

Trial

Phase 1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:58

177Lu-DOTATATE significantly extends PFS in patients with GEP-NETs, regardless of grade or origin

Presented By

Dr Simron Singh, University of Toronto, Canada

Trial

Phase 3, NETTER-2

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:56

Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer

Presented By

Prof. Do-Youn Oh, Seoul National University, Korea

Trial

Phase 3, TOPAZ-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:53

Promising first results of mitazalimab in metastatic pancreatic ductal adenocarcinoma

Presented By

Dr Teresa Macarulla, Vall d’Hebron University Hospital, Spain

Trial

Phase 1/2, OPTIMIZE-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:50

Post-operative MRD status more prognostic than TNM stage

Presented By

Dr Arvind Dasari, MD Anderson Cancer Center, TX, USA

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:48

CAPRI 2 GOIM trial navigates biomarker-driven therapy

Presented By

Dr Giulia Martini, University of Campania Luigi Vanvitelli, Italy

Trial

Phase 2, CAPRI 2 GOIM

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:44

Meta-analysis of triplet therapy in BRAFV600E-mutated mCRC

Presented By

Dr Davi Said G. Celso, Federal University of Viçosa, Brazil

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:41

New analyses validate TAP and CPS scores for PD-L1 expression

Presented By

Prof. Markus Moehler; Prof. Eric Raymond

Trial

Phase 3, RATIONALE-305; RATIONALE-306

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:39

CheckMate 8HW: Nivolumab/ipilimumab in MSI-H/dMMR mCRC

Presented By

Dr Sara Lonardi, Veneto Institute of Oncology, Italy

Trial

Phase 3, CheckMate 8HW

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:39

Sequence effect for third-line treatment of mCRC

Presented By

Prof. Michel Ducreux, Gustave Roussy, France

Trial

Phase 2, SOREGATT

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:36

REGINA meets stage 1 endpoint in rectal cancer and moves to stage 2 with reduced dose regorafenib

Presented By

Dr Francesco Sclafani, Institut Jules Bordet, Belgium

Trial

Phase 2, REGINA

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:34

High efficacy of pembrolizumab combined with standard therapy in patients with MSS/pMMR mCRC and high immune infiltrate

Presented By

Prof. David Tougeron, Poitiers University Hospital, France

Trial

Phase 2, POCHI

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:31

KEYNOTE-585: negative trial, but long-term benefit in PD-L1-high/MSI subgroups?

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, KEYNOTE-585

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:30

Prognostic value of ctDNA in stage III colon cancer

Presented By

Prof. Julien Taieb, Paris Descartes University, France

Trial

Phase 3, IDEA-France, IDEA-Greece

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:28

Neoadjuvant combined immunotherapy also effective in MSS/pMRR CRC

Presented By

Dr Mehraneh Jafari, Weill Cornell Medical Center, NY, USA

Trial

Phase 2, NEST-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:25

Neoadjuvant immunotherapy plus radiation effective in advanced MSI-H rectal cancer

Trial

Phase 2, ECOG-ACRIN EA2201

Type

Peer-reviewed article

21 August 2024 11:19

Peri- or post-operative chemotherapy benefits patients with resectable CRCLM

Presented By

Dr Giacomo Bregni, Brussels University Hospital, Belgium

Trial

Phase 3

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:12

MINOTAUR: Promising phase 1 data for lunresertib plus FOLFIRI

Presented By

Dr Elisa Fontana, Sarah Cannon Research Institute, UK

Trial

Phase 1, MINOTAUR

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:09

TRANSMET meets OS endpoint

Presented By

Dr Maximiliano Gelli, Gustave Roussy, France

Trial

TRANSMET

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:05

ESMO GI 2024 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

ESMO GI 2024

15 July 2024 09:05

ASCO 2024

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Conference

ASCO 2024

18 July 2024 16:08

No survival benefit of tumour debulking for patients with multi-organ metastatic CRC

Presented By

Dr Elske Gootjes, Radboudumc, the Netherlands

Trial

Phase 3, ORCHESTRA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:53

Thermal ablation of small-size colorectal liver metastases is non-inferior to resection

Presented By

Prof. Martijn Meijerink, Amsterdam UMC, the Netherlands

Trial

Phase 3, COLLISION

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:48

Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC

Presented By

Prof. Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CheckMate 8HW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:44

Neoadjuvant checkpoint blockade in MSI-H/dMMR CRC

Trial

Phase 1/2, NICHE-2, NEOPRISM-CRC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:36

CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC

Presented By

Prof. Marwan Fakih, City of Hope Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CodeBreaK 300

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:26

FLOT outperforms CROSS in resectable oesophageal cancer

Presented By

Prof. Jens Höppner, University of Bielefeld, Germany

Trial

Phase 3, ESOPEC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:14

Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC

Presented By

Dr Peter Galle, Universitätsmedizin Mainz, Germany

Trial

Phase 3, CheckMate 9DW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:10

No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer

Presented By

Dr Masafumi Ikeda, National Cancer Center Hospital East, Japan

Trial

Phase 3, GABARNANCE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:06

Benefit of abemaciclib plus fulvestrant after progression on a CDK4/6 inhibitor

Presented By

Prof. Kevin Kalinsky, Emory School of Medicine, GA, USA

Trial

postMONARCH

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:02

ctDNA is prognostic of worse outcomes for CDK4/6 therapy

Presented By

Prof. Sherene Loi, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, monarchE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:56

Adjuvant avelumab significantly improves survival in early TNBC

Presented By

Prof. Pierfranco Conte, University of Padova, Italy

Trial

Phase 3, A-BRAVE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:53

High pCR rate after neoadjuvant Dato-DXd plus durvalumab therapy

Presented By

Dr Jane Meisel, Emory School of Medicine, GA, USA & Dr Rebecca Shatsky, University of California San Diego, CA, USA

Trial

I-SPY2.2

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:38

Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC

Presented By

Prof. Suresh Ramalingam, Emory School of Medicine, GA, USA

Trial

Phase 3, LAURA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:30

First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC

Presented By

Prof. Benjamin Solomon, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, CROWN

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:28

Comparable benefit of video- and in-person-delivered palliative care

Presented By

Dr Joseph Greer, Harvard Medical School, MA, USA

Trial

REACH PC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:25

Consolidation with durvalumab improves survival in LS-SCLC

Presented By

Dr David Spigel, Sarah Cannon Research Institute, TN, USA

Trial

Phase 3, ADRIATIC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:23

Subcutaneous amivantamab non-inferior and more convenient than intravenous amivantamab

Presented By

Dr Natasha Leighl, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, PALOMA-3

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:19

Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma

Presented By

Prof. Christian Blank, Antoni van Leeuwenhoek, the Netherlands

Trial

Phase 3, NADINA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:16

Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma

Presented By

Prof. Axel Hauschild, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PIVOTAL

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:13

Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma

Presented By

Prof. Caroline Robert, Gustave Roussy, France

Trial

Phase 3, ILLUMINATE-301

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:09

Immune-enhancing nutrition does not affect complication rate of radical cystectomy

Presented By

Prof. Jill Hamilton-Reeves, University of Kansas Medical Center, KS, USA

Trial

Phase 3, SWOG S1600

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:05

Biomarkers for treatment of renal cell carcinoma

Trial

Phase 3, CLEAR, KEYNOTE-426, IMmotion010

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:00

ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma

Presented By

Prof. Thomas Powles, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-361

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:51

Highest efficacy of nivolumab/chemotherapy in lymph-node-only metastatic urothelial carcinoma

Presented By

Prof. Matthew Galsky, Tisch Cancer Institute, NY, USA

Trial

Phase 3, CheckMate 901

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:48

Metformin does not prevent progression of low-risk prostate cancer

Presented By

Dr Anthony Joshua, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, MAST

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:46

Baseline ctDNA has both prognostic and predictive value in mCRPC

Presented By

Prof. Johann de Bono, Royal Marsden Hospital, UK

Trial

Phase 3, PSMAfore

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:44

Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT

Presented By

Dr Brad Stish, Mayo Clinic, MN, USA

Trial

Phase 2, Alliance 222001

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:41

Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer

Presented By

Dr Katherine Fuh, University of California San Francisco, CA, USA

Trial

Phase 3, AXLerate-OC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:38

No lymphadenectomy for advanced ovarian cancer without suspicious nodes

Presented By

Prof. Jean-Marc Classe, Nantes Université, France

Trial

Phase 3, CARACO

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:34

SIENDO: Efficacy benefit of selinexor in TP53 wildtype endometrial cancer

Presented By

Dr Vicky Makker, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, SIENDO

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:32

Novel regimen for HR-positive endometrial cancer on the way?

Presented By

Dr Angela Green, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:30

Meet the Trialist: Prof. Giuseppe Curigliano on DESTINY-Breast06

Expert

Prof. Giuseppe Curigliano, University of Milan, Italy

Trial

Phase 3, DESTINY-Breast06

Conference

ASCO 2024

24 June 2024 15:38

IMmotion010 trial: KIM-1 and disease-free survival in RCC

Presented By

Prof. Laurence Albiges, Institut Gustave Roussy, France

Trial

Phase 3, IMmotion010

Conference

ASCO 2024

13 June 2024 15:07

ASCO GI 2024

SABCS 2023

ESMO 2023

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Conference

ESMO 2023

19 December 2023 14:31

Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer

Presented By

Prof. Antonio Gonzalez Martin, Cancer Centre Clinica Universidad de Navarre, Spain

Trial

Phase 3, ANITA

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:43

Short-induction chemotherapy improves survival in advanced cervical cancer

Presented By

Dr Mary McCormack, University College London, UK

Trial

Phase 3, INTERLACE

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:37

Neoadjuvant immune checkpoint blockade safe and effective in MMRd endometrial cancer

Presented By

Dr Marco de Bruyn , University Medical Center Groningen, the Netherlands

Trial

Phase 1, PAM

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:34

Two potential new first-line standards of care in metastatic urothelial cancer

Presented By

Prof. Thomas Powles, Queen Mary University of London, UK

Trial

Phase 3, EV-302/KEYNOTE-A39; CheckMate 901

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:19

LuPSMA and enzalutamide: a promising combination

Presented By

Prof. Louise Emmet, St Vincent’s Hospital Sydney, Australia

Trial

Phase 2, ENZA-p

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:15

No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy

Presented By

Prof. Arlene Siefker-Radtke, MD Anderson Cancer Centre, USA

Trial

Phase 3, THOR

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 11:20

Lifileucel induces a durable response in heavily pretreated mucosal melanoma

Presented By

Dr Evidio Domingo-Musibay, Masonic Cancer Center, USA

Trial

Phase 2, C-144-01

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 11:15

Darovasertib/crizotinib combination: a potential first-line therapy in metastatic uveal melanoma

Presented By

Dr Meridith McKean, Tennessee Oncology, USA

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 11:06

Perioperative durvalumab/FLOT improves pCR in gastric cancer

Presented By

Prof. Salah-Eddin Al-Batran, Northwest Hospital Frankfurt, Germany

Trial

Phase 3, MATTERHORN

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:58

Active surveillance after neoadjuvant chemoradiotherapy in oesophageal cancer

Presented By

Dr Berend van der Wilk, Erasmus Medical Centre, the Netherlands

Trial

Phase 3, SANO

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:48

FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer

Presented By

Prof. Bas Groot Koerkamp, Erasmus Medical Centre, the Netherlands

Trial

Phase 3, PREOPANC-2

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:35

Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma

Presented By

Prof. Aziz Zaanan, Université Paris Cité, France

Trial

Phase 3, GASTROFOX

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:30

Perioperative nivolumab boosts event-free survival in NSCLC

Presented By

Dr Tina Cascone, MD Anderson Cancer Center, USA

Trial

Phase 3, CheckMate 77T

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 09:56

Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC

Presented By

Prof. Herbert Ho Fung Loong, Chinese University of Hong Kong, China

Trial

Phase 3, LIBRETTO-431

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 09:54

Dato-DXd outperforms docetaxel in previously treated patients with metastatic NSCLC  

Presented By

Dr Aaron Lisberg, University of California Los Angeles, USA

Trial

Phase 3, TROPION-LUNG01

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 09:51

First-line and second-line benefit of amivantamab in advanced, EGFR-mutated NSCLC

Presented By

Prof. Nicolas Girard, Institut du Thorax Curie-Montsouris, France

Trial

Phase 3, PAPILLON

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 09:47

Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer

Presented By

Dr Yara Verschoor, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NICHE-3

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 16:04

Selective KRASG12C inhibitor sotorasib leads to superior PFS in colorectal cancer

Presented By

Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori, Italy

Trial

Phase 3, CodeBreak300

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 16:01

Postoperative ctDNA predicts survival in colorectal cancer

Presented By

Dr Yoshiaki Nakamura, National Cancer Centre Hospital East, Japan

Trial

GALAXY

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:55

Overall survival in patients with initially unresectable colorectal liver metastases does not depend on choice of induction regimen 

Presented By

Prof. Cornelis J. Punt, University Medical Center Utrecht, the Netherlands

Trial

Phase 3, CAIRO5

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:53

Benefit of pembrolizumab in TNBC remains after 5 years of follow-up  

Presented By

Prof. Peter Schmid, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-522

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:50

Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer

Presented By

Dr Fatima Cardoso, Champalimaud Clinical Centre, Portugal

Trial

Phase 3, KEYNOTE-756 trial

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:48

Long-term air pollution exposure at both residential and workplace locations increases breast cancer risk

Presented By

Prof. Béatrice Fervers, Centre Léon Bérard, France

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:45

Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy

Presented By

Dr Aditya Bardia, Massachusetts General Hospital, USA

Trial

Phase 3, TROPION-Breast01

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:41

Can radiotracers predict response to PD-L1 inhibitors in early NSCLC?

Expert

Prof. Gary Cook, King's College London and Guy's and St Thomas Hospitals, UK

Conference

ESMO 2023

20 November 2023 16:01

The importance of detecting early NSCLC

Expert

Prof. Witold Rzyman, Medical University of Gdańsk, Poland

Conference

ESMO 2023

20 November 2023 15:34

ESMO 2023 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ESMO 2023

8 November 2023 13:46

ASCO 2023

Real-world data support new SOC in patients with SCLC

Expert

Prof. Nicolas Girard, Institut Curie, Paris, France

Trial

IFCT 1905-CLINATEZO

10 October 2023 17:24

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Conference

ASCO 2023

2 August 2023 10:18

7-year outcomes of PRODIGE 23 trial

Presented By

Prof. Thierry Conroy, Institut de Cancérologie de Lorraine, France

Trial

Phase 3, PRODIGE 23

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 10:04

Neoadjuvant chemotherapy may be viable option in locally advanced colon cancer

Presented By

Dr Lars Hendrik Jensen, University of Southern Denmark, Denmark

Trial

Phase 3, NeoCol

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 10:00

De-escalation of neoadjuvant treatment of locally advanced rectal cancer is non-inferior

Presented By

Dr Deborah Schrag, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, PROSPECT

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:58

SONIA: No survival benefit with first-line versus second-line CDK4/6 inhibition in metastatic breast cancer

Presented By

Prof. Gabe Sonke, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, SONIA

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:55

Adjuvant ribociclib improves invasive DFS in early breast cancer

Presented By

Prof. Dennis Slamon, David Geffen School of Medicine, CA, USA

Trial

Phase 3, NATALEE

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:52

Gene expression profiles predict benefit of neoadjuvant immune checkpoint therapy in triple-negative breast cancer

Presented By

Dr Hanna Huebner, Erlangen University Hospital, Germany

Trial

Phase 2, GeparNuevo

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:49

Adding pembrolizumab to perioperative chemotherapy improves EFS in early-stage NSCLC

Presented By

Prof. Heather Wakelee, Stanford University, CA, USA

Trial

Phase 3, KEYNOTE-671

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:44

TTFields therapy: a new treatment modality for metastatic NSCLC

Presented By

Prof. Ticiana Leal, Emory University, GA, USA

Trial

Phase 3, LUNAR

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:42

Adding chemotherapy to EGFR TKI does not improve OS in advanced EGFR-mutated NSCLC

Presented By

Dr Shintaro Kanda, Shinshu University, Japan

Trial

Phase 3, AGAIN

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:39

No improved OS in pancreatic cancer after neoadjuvant mFOLFIRINOX

Presented By

Prof. Knut Labori, Oslo University Hospital, Norway

Trial

Phase 2, NorPACT-1

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:35

AI detects gastric cancer with high accuracy in common blood tests

Presented By

Mr Tsz Chun Bryan Wong, Hong Kong University of Science and Technology, Hong Kong

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:34

Response-directed treatment personalisation in stage III melanoma

Presented By

Dr Irene Reijers, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, OpACIN-neo, PRADO

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:30

Prognostic and predictive biomarkers in patients with resected stage IIB/C melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Trial

Phase 3, CheckMate76K

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:27

Combining PARP inhibition and androgen receptor-signalling inhibition improves radiographic progression-free survival in HRR-deficient mCRPC

Presented By

Prof. Karim Fizazi, Institute Gustave Roussy, France

Trial

Phase 3, TALAPRO-2

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:24

Erdafitinib outperforms chemotherapy in FGFR-altered advanced urothelial cancer

Presented By

Dr Yohann Loriot, Gustave Roussy Cancer Institute, France

Trial

Phase 3, THOR

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:20

Probiotic CBM588 seems to improve clinical effect cabozantinib/nivolumab in mRCC

Presented By

Dr Hedyeh Ebrahimi, Tehran University of Medical Sciences, Iran

Trial

Phase 1

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:11

Exploratory analysis of IMvigor130 trial finds no OS benefit from atezolizumab in subgroups

Presented By

Dr Enrico Grande, MD Anderson Cancer Center, Spain

Trial

Phase 3, IMvigor130

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:08

Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer

Presented By

Dr Philipp Harter, Kliniken Essen-Mitte, Germany

Trial

Phase 3, DUO-O

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:44

First-line nivolumab-AVD improves PFS both in adult and paediatric patients with advanced Hodgkin lymphoma

Presented By

Prof. Alex Herrera, City of Hope Medical Center, CA, USA

Trial

Phase 3, SWOG S1826

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:38

Vorasidenib successfully targets IDH1/2-mutated glioma

Presented By

Dr Ingo Mellinghoff, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, INDIGO

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:33

IMbrave050: Adjuvant atezolizumab plus bevacizumab provides landmark recurrence-free survival for HCC

Expert

Prof. Masatoshi Kudo, Kindai University, Japan

Conference

ASCO 2023

Type

Peer-reviewed article

17 July 2023 14:51

What can real-world evidence teach us about atezolizumab plus bevacizumab in HCC?

Expert

Dr Cha Len Lee, University of Toronto, Canada

Conference

ASCO 2023

Type

Peer-reviewed article

17 July 2023 14:47

ASCO 2023 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO 2023

26 June 2023 03:07

SABCS 2022

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Conference

SABCS 2022

1 February 2023 18:46

Racial disparity in the tumour microenvironment

Presented By

Dr Burcu Karadal-Ferrena, Albert Einstein College of Medicine, NY, USA

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:42

Chemo-endocrine therapy worse for cognition than endocrine therapy alone

Presented By

Dr Irene Kang, City of Hope Orange County, CA, United States

Trial

RxPONDER PRO

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:36

Resistance to CDK4/6 inhibitors is likely due to expansion of pre-existing resistant clones

Presented By

Dr Cristina Guarducci, Dana-Farber Cancer Institute, MA, USA

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:32

Baseline CTC count can guide first-line treatment in HR-positive/HER-negative metastatic breast cancer

Presented By

Prof. François-Clément Bidard, Institut Curie, France

Trial

Phase 3, STIC CTC

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:30

Germline pathogenic variants for breast cancer also increase contralateral breast cancer risk

Presented By

Prof. Siddhartha Yadav, Mayo Clinic, MN, USA

Trial

CARRIERS

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:27

Low-dose tamoxifen still prevents recurrence from non-invasive breast cancer

Presented By

Dr Andrea De Censi, Ospedali Galliera, Italy

Trial

Phase 3, TAM-01

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:24

Endocrine interruption to pursue pregnancy does not impact short-term disease in breast cancer

Presented By

Dr Ann Partridge, Dana-Farber Cancer Institute, MA, USA

Trial

POSITIVE

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:22

ZNF689 deficiency promotes intratumour heterogeneity and resistance to immune checkpoint blockade in TNBC

Presented By

Dr Li-Peng Ge, Fudan University Shanghai Cancer Center, China

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:17

Oestradiol represses anti-tumoural immune response to promote progression of brain metastases

Presented By

Dr Maria Contreras-Zarate, University of Colorado, CO, USA

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:14

Benefit of adjuvant abemaciclib continues to deepen at longer follow-up

Presented By

Prof. Stephen Johnston, The Royal Marsden NHS Foundation Trust, UK

Trial

Phase 3, monarchE

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:10

First-line ribociclib plus endocrine therapy outperforms combination chemotherapy

Presented By

Dr Yen-Shen Lu, National Taiwan University Hospital, Taiwan

Trial

Phase 2, RIGHT Choice

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:07

Treatment options beyond CDK4/6 inhibition

Presented By

Dr Erica Mayer (Dana-Farber Cancer Institute, MA, USA); Prof. Virginia Kaklamani (University of Texas Health Sciences Center, TX, USA);

Trial

PACE; EMERALD; SERENA-2; CAPItello-291; VERITAC

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:03

Trastuzumab deruxtecan effective in both second-line and neoadjuvant setting

Presented By

Dr Ian Krop (Yale Cancer Center, CT, USA); Prof. Sara Hurvitz (David Geffen School of Medicine, CA, USA); Prof. Aditya Bardia (Harvard Medical School, MA, USA)

Trial

Phase 3, DESTINY-Breast02; DESTINY-Breast03; TRIO-US B-12 TALENT

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 17:51

Anti-PD-1/anti-LAG-3 combination highly effective in HER2-negative breast cancer

Presented By

Prof. Claudine Isaacs, Georgetown University Medical Center, DC, USA

Trial

Phase 2, I-SPY 2

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 17:42

MammaPrint test predictive for benefit of extended endocrine therapy

Presented By

Dr Laura van ‘t Veer, UCLA, CA, USA

Trial

Phase 3, IDEAL

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 17:32

ASCO GI 2023

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Conference

ASCO GI 2023

17 March 2023 09:47

First-line NALIRIFOX superior to standard treatment in mPDAC

Presented By

Prof. Zev Wainberg, University of California Los Angeles, CA, USA

Trial

Phase 3, NAPOLI-3

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:37

Novel approach delivers quality-of-life benefits for patients with pancreatic cancer

Presented By

Dr Yaacov Lawrence, Sheba Medical Center, Israel

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:34

Palliative radiation therapy improves hepatic pain in HCC and liver metastasis

Presented By

Prof. Laura Dawson, Princess Margaret Cancer Centre, Canada

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:30

Improved survival following postoperative sorafenib plus TACE in HCC

Presented By

Prof. Ming Kuang, The First Affiliated Hospital, China

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:28

Quality-of-life benefits for tislelizumab in uHCC

Presented By

Prof. Richard Finn, University of California Los Angeles, CA, USA

Trial

Phase 3, RATIONALE-301

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:26

Stereotactic body radiation therapy beneficial for patients with locally advanced HCC

Presented By

Prof. Laura Dawson, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, NRG/RTOG1112

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:23

SWOG 1815, first-ever phase 3 trial in BTC, fails

Presented By

Prof. Rachna Shroff, University of Arizona Cancer Center, AZ, USA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:20

IMbrave 151 missed primary endpoint in advanced BTC

Presented By

Prof. Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 2, IMbrave151

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:15

Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC

Presented By

Dr Junji Furuse, Kanagawa Cancer Center, Japan

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:11

Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC

Presented By

Prof. Anthony El-Khoueiry, Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 1, C-800

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:06

Mutation-based selection to identify patients suitable for panitumumab treatment

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, PARADIGM

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:01

Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT

Presented By

Prof. Jaw-Yuan Wang, Pingtung Hospital, Taiwan

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:58

ctDNA appears useful in monitoring patients with anal cancer undergoing CRT

Presented By

Dr Janet Alvarez, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:55

SUNLIGHT trial meets primary endpoint in refractory metastatic CRC

Presented By

Prof. Josep Tabernero, Val d’Hebron University Hospital and Institute of Oncology, Spain

Trial

Phase 3, SUNLIGHT

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:45

Does cell-free DNA influence MRD testing in post-operative colon cancer?

Presented By

Dr Stacey Cohen, University of Washington, WA, USA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:41

OPERA: surgery may be avoided with adequate therapy in rectal cancer

Presented By

Prof. Arthur Sun Myint, Clatterbridge Cancer Centre, UK

Trial

Phase 3, OPERA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:39

Can we improve total neoadjuvant therapy for rectal cancer?

Presented By

Dr Thomas George, University of Florida, FL, USA

Trial

Phase 2, NRG-GI002

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:36

Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, SPOTLIGHT

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:31

Regorafenib offers survival benefit for patients with pre-treated gastric cancer

Presented By

Prof. Nick Pavlakis, University of Sydney, Australia

Trial

Phase 3, INTEGRATE IIa

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:24

Radiotherapy or not in locally advanced oesophageal or junctional cancer?

Presented By

Prof. Maeve Lowery, St James’s Hospital, Ireland

Trial

Phase 3, Neo-AEGIS

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:20

Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial

Presented By

Dr Filippo Pietrantonio, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 2, INFINITY

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:19

S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?

Presented By

Dr Souya Nunobe, Cancer Institute Hospital, Japan

Trial

Phase 3, OPAS-1

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:18

LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer

Presented By

Dr Shinichi Sakuramoto, Saitama Medical University International Medical Center, Japan

Trial

JCOG1401

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:15

3-year follow-up data confirms benefits of nivolumab plus chemotherapy

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer, NY, USA

Trial

Phase 3, CheckMate 649

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:10

Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer

Presented By

Dr Ken Kato, National Cancer Center Hospital, Japan

Trial

Phase 3, CheckMate 648

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:02

Promising phase 2 results for HER-Vaxx in gastric cancer

Presented By

Dr Tanuj Chawla, Tata Medical Center, India

Trial

Phase 2, HERIZON

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:00

ASCO GI 2023 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

ASCO GI 2023

6 February 2023 23:36

ESMO 2022

Letter from the Editor

Editor

Dr Stefan Rauh, the Centre Hospitalier Emile Mayrisch, Esch, Luxembourg

Conference

ESMO 2022

17 November 2022 01:22

Adding first-line pembrolizumab to CRT in locally advanced HNSCC does not significantly prolong survival or event-free survival

Presented By

Prof. Jean-Pascal Machiels, Cliniques Universitaires Saint-Luc, Belgium

Trial

Phase 3, KEYNOTE-412

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 01:12

5-FU-free chemotherapy combination as an alternative for first-line treatment of recurrent or metastatic HNSCC

Presented By

Dr Marcin Dzienis, Gold Coast University Hospital, Australia

Trial

Phase 4, KEYNOTE-B10

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 01:06

Epstein Barr virus-specific autologous cytotoxic T lymphocytes do not improve survival in nasopharyngeal carcinoma

Presented By

Dr Han Chong Toh, National Cancer Centre, Singapore

Trial

Phase 3, VANCE

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 01:02

OS benefit for advanced ovarian cancer patients treated with maintenance olaparib

Presented By

Prof. Isabelle Ray-Coquard, Centre Léon Bérard, France

Trial

Phase 3, PAOLA-1/ENGOT-ov25

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:57

Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer

Presented By

Prof. Keiichi Fujiwara, Saitama Medical University, Japan

Trial

GOTIC-002 LUFT

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:52

Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy

Presented By

Prof. Robert Motzer, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, CheckMate 914

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:46

Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy

Presented By

Prof Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, COSMIC-313

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:41

Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence

Presented By

Dr Axel Bex, The Royal Free London NHS Foundation Trust, UK

Trial

Phase 3, IMmotion-010

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:28

Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

Presented By

Prof. Gerhardt Attard, UCL Cancer Institute London, UK

Trial

Phase 3, STAMPEDE

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:23

Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer

Presented By

Prof. Chris Parker, The Royal Marsden Hospital, UK

Trial

RADICALS-HD

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:17

Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer

Presented By

Dr Rahul Aggarwal, University of California San Francisco, CA, USA

Trial

Phase 3, PRESTO

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:13

Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab

Presented By

Prof. John Haanen, Netherlands Cancer Institute, the Netherlands

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:29

Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanomas

Presented By

Dr Sapna Patel, MD Anderson Cancer Center, TX, USA

Trial

Phase 2, SWOG S1808

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:26

Survival-benefit of neoadjuvant T-VEC maintained over 5 years of follow-up

Presented By

Prof. Reinhard Dummer, University of Zürich, Switzerland

Trial

T-VEC

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:24

Baseline ctDNA predicts survival in resected stage III–IV melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Trial

Phase 3, CheckMate 915

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:21

A pathway from air pollution to lung cancer in non-smokers identified

Presented By

Prof. Charles Swanton, University College London, UK

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:17

Selective KRASG12C inhibitor sotorasib demonstrates superior PFS and ORR compared to docetaxel in previously treated patients with NSCLC

Presented By

Dr Melissa Johnson, Sarah Cannon Research Institute, TN, USA

Trial

Phase 3, CodeBreaK 200

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:14

Promising clinical activity of tepotinib plus osimertinib in NSCLC with MET amplification after progression on first-line osimertinib

Presented By

Prof. Julien Mazières, CHU de Toulouse, France

Trial

Phase 2, INSIGHT-2

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:10

High pathological responses in borderline resectable NSCLC patients after induction with dual immunotherapy and concurrent chemoradiotherapy

Presented By

Dr Idris Bahce, Amsterdam UMC, the Netherlands

Trial

Phase 2, INCREASE

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:05

Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer

Presented By

Prof. Marleen Kok, Netherlands Cancer Institute, the Netherlands)

Trial

Phase 2, BELLINI

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:01

OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant

Presented By

Prof. Matthew Goetz, Mayo Clinic Rochester, MN, USA

Trial

Phase 3, MONARCH 3

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:48

OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer

Presented By

Prof. Hope Rugo, Helen Diller Family Comprehensive Cancer Centre, CA, USA

Trial

Phase 3, TROPiCS-02

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:43

Deep learning models predict the risk of relapse and the mutational profile in GIST

Presented By

Dr Raul Perret, Institute Bergonié, France

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:40

Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC

Presented By

Prof. Richard Finn, David Geffen School of Medicine, CA, USA

Trial

Phase 3, LEAP-002

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:37

New, highly selective inhibitor of FGFR2 driver alterations and resistance mutations

Presented By

Prof. Antoine Hollebecque, Institut Gustave Roussy, France

Trial

Phase 1/2, REFOCUS

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:35

Chemo-immunotherapy in gastric cancer is more effective when administered in parallel

Presented By

Prof.  Sylvie Lorenzen, Klinikum rechts der Isar, TU München, Germany

Trial

Phase 2, Moonlight

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:31

High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer

Presented By

Dr Miriam Chalabi, Netherlands Cancer Institute, the Netherlands

Trial

NICHE-2

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:28

Fruquintinib: a potential new treatment for patients with refractory mCRC

Presented By

Prof. Nageshwara Arvind Dasari, MD Anderson Cancer Centre, TX, USA

Trial

Phase 3, FRESCO-2

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:21

Second-line avelumab is effective in patients with MSI-H/dMMR mCRC

Presented By

Prof. Julien Taieb, Hopital European George Pompidou, France

Trial

Phase 2, SAMCO-PRODIGE 54

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:13

WCLC 2022

ASCO 2022

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Conference

ASCO 2022

5 August 2022 15:44

Bacterial decolonisation effective against radiation dermatitis

Presented By

Ms Yana Kost, Albert Einstein College of Medicine, NY, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:38

New standard-of-care for cisplatin-ineligible locally advanced head and neck squamous cell carcinoma

Presented By

Prof. Vanita Noronha, Tata Memorial Hospital, India

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:35

Ifosfamide is likely to be the go-to therapy in recurrent Ewing sarcoma 

Presented By

Dr Martin McCabe, University of Manchester, UK

Trial

Phase 3, rEECur

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:32

Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma 

Presented By

Prof. Eric Bouffet, University of Toronto, Canada

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:30

Primary results of rucaparib in ovarian cancer 

Presented By

Prof. Bradley Monk, University of Arizona, AZ, USA

Trial

Phase 3, ATHENA-MONO

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:28

Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer 

Presented By

Dr Domenica Lorusso, San Raffaele Scientific Institute, Italy

Trial

Phase 3, MIT023

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:25

Encouraging results of relacorilant in ovarian cancer

Presented By

Prof. Nicoletta Colombo, University of Milan, Italy

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:23

Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer  

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 3, PARADIGM

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:19

Spectacular results for dostarlimab in mismatch repair deficient rectal cancer 

Presented By

Dr Andrea Cercek, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:14

Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases

Presented By

Prof. Cornelis Punt, University Medical Center Utrecht, the Netherlands

Trial

Phase 3, CAIRO5

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:11

To resect or not to resect primary tumours in stage IV colon cancer?

Presented By

Prof. Jürgen Weitz, Technische Universität Dresden, Germany

Trial

SYNCHRONOUS

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:08

Novel treatment option for KRAS wildtype pancreatic cancer 

Presented By

Prof. Shukui Qin, Cancer Center of Jinling Hospital, China

Trial

Phase 3, NOTABLE

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:03

Autologous stem cell transplantation plus RVd improves PFS in multiple myeloma  

Presented By

Prof. Paul Richardson, Harvard Medical School, MA, USA

Trial

Phase 3, DETERMINATION

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:33

Novel first-line treatment option for mantle cell lymphoma 

Presented By

Prof. Michael Wang, Anderson Cancer Center, TX, USA

Trial

Phase 3, SHINE

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:30

Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma

Presented By

Prof. Juan Du, Shanghai Chang Zheng Hospital, China

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:24

Exploratory treatment options fail in ccRCC 

Presented By

Prof. Thomas Powles, University of London, UK

Trial

Phase 2, CALYPSO

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:18

Adjuvant everolimus did not benefit high-risk renal cell carcinoma 

Presented By

Dr Christopher W. Ryan, Oregon Health & Science University, OR, USA

Trial

Phase 3, EVEREST

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:14

Cabozantinib fails as first-line maintenance therapy in urothelial cancer

Presented By

Prof. Robert Jones, University of Glasgow, UK

Trial

Phase 2, ATLANTIS

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:11

177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC

Presented By

Prof. Michael Hofman, Peter McCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:08

Enzalutamide performs well in metastatic hormone-sensitive prostate cancer

Presented By

Prof. Ian Davis, Monash University, Australia

Trial

Phase 3, ENZAMET

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:04

First results on distant metastasis-free survival in stage II melanoma 

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 3, KEYNOTE-716

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 13:54

Higher response rates for concurrent triple therapy versus sequential therapy in melanoma

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 2, NeoTrio

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 13:50

Additional tiragolumab does not help patients with untreated small cell lung cancer 

Presented By

Dr Charles Rudin, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, SKYSCRAPER-02

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:42

Success for serplulimab plus chemotherapy in small cell lung cancer

Presented By

Prof. Ying Cheng, Jilin Cancer Hospital, China

Trial

Phase 3, ASTRUM-005

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:38

Adagrasib safe and clinically active in non-small cell lung cancer

Presented By

Dr Alexander Spira, Virginia Cancer Specialists Research Institute, VA, USA

Trial

Phase 2, KRYSTAL-1

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:33

Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer

Presented By

Prof. Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center, Australia

Trial

Phase 3, CheckMate 227

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:29

Effect of KRAS mutations and PD-L1 expression on therapy response in non-small cell lung cancer

Presented By

Dr Oladimeji Akinboro, US Food and Drug Administration, MD, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:26

Sacituzumab govitecan meets primary endpoint 

Presented By

Prof. Hope Rugo, University of California San Francisco, CA, USA

Trial

Phase 3, TROPiCS-02

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:11

Shaky OS results of palbociclib in ER-positive/HER2-negative breast cancer 

Presented By

Prof. Richard Finn, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, PALOMA-2

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:09

Practice-changing results of T-DXd in HER2-low breast cancer 

Presented By

Prof. Shanu Modi, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DESTINY-Breast04

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:04

SET2,3 to inform on chemotherapy decisions in ER-positive breast cancer

Presented By

Dr Otto Metzger, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, CALGB9741

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:59

Metastasis-directed therapy fails in oligometastatic breast cancer

Presented By

Dr Steven Chmura, University of Chicago, IL, USA

Trial

Phase 2, NRG-BR002

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:34

Analysis by residual cancer burden further clarifies effect of pembrolizumab

Presented By

Prof. Lajos Pusztai, Yale School of Medicine, CT, USA

Trial

Phase 3, KEYNOTE-522

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:26

Contribution of metastatic therapies on mortality reduction in breast cancer

Presented By

Prof. Jennifer Caswell-Jin, Stanford University, CA, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:19

Radiotherapy may be omitted in breast cancer patients 

Presented By

Prof. Timothy Whelan, McMaster University, Canada

Trial

LUMINA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 10:59

Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer

Presented By

Prof. Kevin Kalinsky, Winship Cancer Institute of Emory University, GA, USA

Trial

Phase 2, MAINTAIN

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 10:53

7-gene biosignature: Benefits of endocrine therapy and radiotherapy in breast cancer risk groups

Presented By

Dr Pat Whitworth, Nashville Breast Cancer Center, TN, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 10:44

ASCO 2022 Highlights Podcast

Presented By

Dr Robert van den Heuvel, Medicom

Conference

ASCO 2022

21 June 2022 09:38

ELCC 2022

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

Conference

ELCC 2022

25 May 2022 12:58

Real-world treatment and survival in early-stage NSCLC

Presented By

Dr Howard West, City of Hope Comprehensive Cancer Center, CA, USA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:44

Consistent efficacy of osimertinib in Chinese and global population

Presented By

Dr Jie Wang, Beijing Cancer Hospital, China

Trial

Phase 3, ADAURA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:43

Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC

Presented By

Dr Chao Lyu, Beijing Cancer Hospital, China

Trial

Phase 2, NEOS

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:43

Peri-operative survival in bilobectomy is comparable with that of left pneumonectomy

Presented By

Dr Andrew Li, Yale School of Medicine, CT, USA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:42

Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy

Presented By

Dr Marta Casarrubios, Hospital Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:41

Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

Presented By

Dr Yuankai Shi, National Cancer Center, China

Trial

Phase 3, FURLONG

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:41

Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC

Presented By

Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC

Presented By

Prof. Byoung Chul Cho, Yonsei Cancer Center Seoul, South Korea

Trial

Phase 1/2, ALKA-372-001, STARTRK-1, STARTRK-2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy

Presented By

Dr Shun Lu, Shanghai Chest Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

Savolitinib is effective in patients with MET-mutated NSCLC

Presented By

Dr Shun Lu, Shanghai Chest Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:39

Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC

Presented By

Dr Yunpeng Yang, Sun Yat-sen University Cancer Center, China

Trial

Phase 3, ORIENT-11

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:39

Updated results of CameL-sq trial confirm benefit of camrelizumab

Presented By

Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China

Trial

Phase 3, CameL-sq

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:38

No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC

Presented By

Dr Delvys Rodriguez-Abreu, Universidad de Las Palmas de Gran Canaria, Spain

Trial

Phase 3, KEYNOTE-598

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:38

In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy

Presented By

Dr Francesco Cortiula, Maastricht University Medical Center, the Netherlands

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC

Presented By

Dr Lukas Käsmann, University Hospital Munich, Germany

Trial

Phase 3

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Durvalumab after sequential CRT safe in stage III, unresectable NSCLC

Presented By

Dr Marina Garassino, University of Chicago, IL, USA

Trial

Phase 2, PACIFIC-6

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC

Presented By

Prof. Rina Hui, University of Sydney, Australia

Trial

Phase 3, PACIFIC

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By

Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, POSEIDON

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:36

Total metabolic tumour volume: a new potential prognostic factor in SCLC

Presented By

Dr Elisa Andrini, Sant'Orsola-Malpighi University Hospital, Italy

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Radiation dose on oesophagus predicts OS in SCLC patients treated with chemoradiotherapy

Presented By

Dr Bilal Tahir, University of Sheffield, United Kingdom

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Characteristics of long-term survivors in the CASPIAN trial

Presented By

Dr Niels Reinmuth, Asklepios Lung Clinic, Germany

Trial

Phase 3, CASPIAN

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Outcomes of real-world CANTABRICO trial match results from CASPIAN

Presented By

Dr Dolores Isla, Hospital Clinico Universitario Lozano Blesa, Spain

Trial

CANTABRICO

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:33

Lung cancer diagnosis with liquid biopsy of peripheral blood cells

Presented By

Dr Andreas Thomsen, University of Freiburg, Germany

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:32

Rare EGFR mutations as oncogenic drivers

Presented By

Dr Alfredo Addeo (University Hospital of Geneva, Switzerland) and Dr Giulia Pasello (Veneto Institute of Oncology, Italy)

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:32

Decline in lung cancer mortality is almost exclusive to men

Presented By

Dr Philip Baum, Thoraxklinik Heidelberg, Germany

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:32

ELCC 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ELCC 2022

19 April 2022 10:43

ASCO GU 2022

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch

Conference

ASCO GU 2022

8 April 2022 11:36

First-line treatment with olaparib significantly improves PFS in mCRPC

Presented By

Dr Fred Saad, Centre Hospitalier de l’Université de Montréal, Canada

Trial

Phase 3, PROpel

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC

Presented By

Dr Kim Chi, University of British Columbia, Canada

Trial

Phase 3, MAGNITUDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

Darolutamide improves OS in mHSPC

Presented By

Dr Matthew Smith, Massachusetts General Hospital Cancer Center, MA, USA

Trial

Phase 3, ARASENS

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide

Presented By

Dr Axel Merseburger, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PRESIDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence

Presented By

Dr David Schuster, Emory University School of Medicine, GA, USA

Trial

Phase 3, SPOTLIGHT

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel

Presented By

Prof. Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:23

Artificial intelligence improves prediction of long-term outcomes

Presented By

Dr Osama Mohamad, University of California San Francisco, CA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer

Presented By

Prof. Neil Fleshner, Princess Margaret Cancer Centre, Canada

Trial

Phase 2, ACDC-RP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By

Dr Guilhem Roubaud, Institut Bergonié, France

Trial

Phase 3, PEACE-1

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity

Presented By

Dr Xin Gao, Massachusetts General Hospital, MA, USA

Trial

Phase 2, ARDENT

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma

Presented By

Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, BAYOU

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:19

Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma

Presented By

Dr Simon Crabb, University of Southampton, UK

Trial

Phase 2, ATLANTIS

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC

Presented By

Dr Sam Chang, Vanderbilt University Medical Center, TN, USA

Trial

Phase 3, QUILT-3.032

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma

Presented By

Dr Yohann Loriot, Institut Gustave Roussy, France

Trial

Phase 3, LEAP-011

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Maintenance niraparib fails to improve PFS in advanced urothelial cancer

Presented By

Dr Francesca Vignani, Ordine Mauriziano Hospital, Italy

Trial

Phase 2, Meet-URO12

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

First-line avelumab shows clinical activity in advanced urothelial carcinoma

Presented By

Dr Roberto Iacovelli, Catholic University of Rome, Italy

Trial

Phase 2, ARIES

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma

Presented By

Dr Wesley Yip, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma

Presented By

Prof. Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-TCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer

Presented By

Dr Petros Grivas, University of Washington, WA, USA

Trial

Phase 2, TROPHY-U-01

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:16

Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin

Presented By

Prof. Daniel Petrylak, Yale School of Medicine, CT, USA

Trial

Phase 1/2, EV-103

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:16

High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib

Presented By

Dr Axel Bex, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NeoAvAx

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up

Presented By

Dr Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE-564

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC

Presented By

Dr Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-RCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Combined nivolumab/axitinib treatment elicits good response in metastatic RCC

Presented By

Dr Matthew Zibelman, Fox Chase Cancer Center, PA, USA

Trial

Phase 1/2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Folliculin mutations not associated with sporadic chromophobe RCC

Presented By

Dr Joseph Jacob, Upstate University Hospital, NY, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Differential patterns of molecular alterations among sites of metastasis in RCC

Presented By

Dr Rana McKay, University of California San Diego, CA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC

Presented By

Dr Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center, DC, USA

Trial

Phase 2, HCRN GU16-260

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

HPV-positive and HPV-negative penile squamous cell carcinoma are molecularly distinct tumours

Presented By

Dr Bassel Nazha, Emory University, GA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:11

Atezolizumab does not improve survival in advanced penile cancer

Presented By

Dr Hielke-Martijn de Vries, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, PERICLES

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:11

Biomarkers to distinguish necrosis from teratoma before pcRPLND in testicular cancer

Presented By

Dr Tim Nestler, University of Cologne, Germany

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:10

ASCO GU 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GU 2022

14 March 2022 07:21